Invention Grant
- Patent Title: Macrocyclic compound and use thereof
-
Application No.: US17299659Application Date: 2019-12-04
-
Publication No.: US11518763B2Publication Date: 2022-12-06
- Inventor: Shigemitsu Matsumoto , Ryoma Hara , Naoyoshi Noguchi , Hideto Fukushi , Ayumu Niida , Satoshi Sasaki , Minoru Ikoma , Toshitake Kobayashi , Tsuyoshi Maekawa
- Applicant: SCOHIA PHARMA, INC.
- Applicant Address: JP Kanagawa
- Assignee: SCOHIA PHARMA, INC.
- Current Assignee: SCOHIA PHARMA, INC.
- Current Assignee Address: JP Kanagawa
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
- Priority: JPJP2018-228234 20181205
- International Application: PCT/JP2019/048593 WO 20191204
- International Announcement: WO2020/116660 WO 20200611
- Main IPC: C07D471/18
- IPC: C07D471/18 ; C07D491/22 ; C07D498/16 ; C07D498/22

Abstract:
A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.
Public/Granted literature
- US20220119391A1 MACROCYCLIC COMPOUND AND USE THEREOF Public/Granted day:2022-04-21
Information query